

Classification	Shared Growth	Shared Growth Policy	Date of Revision	2021.08
Page	②		Revision No.	0.1

1. Overview

Partners of SK Biopharmaceuticals can be divided mainly into raw material suppliers, contract manufacturing organizations (CMOs), and suppliers for the materials necessary for overall operation. With no owned production facility, SK Biopharmaceuticals carries out all the manufacturing-related operations in the commercialization phase of new drugs after marketing approval through close cooperation with CMOs, ranging from procurement of raw materials, product production, quality control to process improvement. SK Biopharmaceuticals is expanding collaboration with not only CMOs but also material procurement partners and has introduced and faithfully implemented four action policies. (fair and transparent selection of partners through a procurement bidding system, fostering a fair and transparent trading environment, training support for partners, and discovery of collaborative tasks)

2. Action Policies

(1) Fair and transparent selection of partners through a procurement bidding system

SK Biopharmaceuticals issues electronic tenders fairly and transparently using the procurement bidding system ('epro').

(2) Fostering a fair and transparent trading environment

SK Biopharmaceuticals is dedicated to fostering a fair and transparent trading environment in accordance with its procurement policies while strengthening internal/external inspections by the Compliance Team.

(3) Training support for partners

SK Biopharmaceuticals provides its partners with various training opportunities aiming

Classification	Shared Growth	Shared Growth Policy	Date of Revision	2021.08
Page	②		Revision No.	0.1

to create and nurture a community for co-prosperity.

(4) Discovery of collaborative tasks

SK Biopharmaceuticals has worked with critical partners to discover and monetize collaborative tasks as a part of its commitment to shared growth.